India’s Pharma Giants Beyond the Stock Market

 

BIZ MASALA FEATURE  •  INDIA’S PHARMA LANDSCAPE

Hetero, Serum Institute, Intas and Bharat Biotech show how privately controlled and unlisted businesses can shape medicines, vaccines and global healthcare.

By Murthy ASR | Biz Masala

HERO IMAGE | Original supplied portraits arranged in the requested order: Binish Chudgar, Dr. Krishna Ella, Vamsi Krishna Bandi and Adar Poonawalla.

THE BIG IDEA Some of India’s most consequential pharmaceutical businesses are not household names on the stock exchange. Their influence is measured instead in manufacturing capacity, vaccine doses, research, global supply chains and the ability to scale medicines.

The other side of Indian pharma

India’s pharmaceutical story is often told through listed companies, their quarterly results and stock-market valuations. But another part of the industry operates away from the daily share-price ticker: companies that are privately held or whose shares are not listed on public exchanges.

These businesses are not all alike. Some focus on generic medicines and active pharmaceutical ingredients; others specialise in vaccines, biologics or complex formulations. Their ownership structures also differ. “Unlisted” means a company’s shares are not traded on a public stock exchange; it does not automatically mean the company is small, family-run or a private limited company.

Four names illustrate the range of this ecosystem: Hyderabad-based Hetero, Pune-based Serum Institute of India, Ahmedabad-based Intas Pharmaceuticals and Hyderabad’s Bharat Biotech. Each has built a different route to scale—and each shows why the country’s pharmaceutical influence cannot be understood through listed-market rankings alone.

Hetero: scale built around APIs and generics

Hetero’s office building in Hyderabad. Photo supplied for this Biz Masala feature.

Founded by Dr. B. Parthasaradhi Reddy in 1993, Hetero began as an active pharmaceutical ingredient (API) player and developed into a global pharmaceutical group spanning APIs, generic formulations, biosimilars and related services. The company describes itself as one of India’s largest privately held pharmaceutical businesses, with a presence in more than 145 countries and more than 36 manufacturing facilities.

Its strengths include APIs—the ingredients that give medicines their therapeutic effect—and finished dosage forms, the tablets, capsules, injectables and other products patients use. Hetero has also built a significant position in antiretroviral medicines used to treat HIV/AIDS. That combination of ingredient chemistry, manufacturing and global distribution gives it a role across multiple points in the medicine supply chain.

The business challenge is not simply to make more. Pharmaceutical manufacturers must maintain consistent quality, navigate different regulatory systems, manage supply reliability and keep investing as competition and product complexity rise. Hetero’s next phase will be judged by how effectively it sustains those capabilities while expanding into newer therapies and markets.

Serum Institute: vaccine scale with a public-health mission

The Serum Institute of India campus. Photo supplied for this Biz Masala feature.

Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla to produce life-saving immunobiologicals that were in short supply and expensive to import. The company says it is the world’s largest vaccine manufacturer by number of doses produced and sold globally. Its portfolio includes vaccines against diseases such as polio, diphtheria, tetanus, pertussis, measles, mumps, rubella and others.

Vaccines operate in a different commercial and scientific environment from many generic medicines. They require specialised biological manufacturing, rigorous quality controls, long development cycles and the ability to supply large volumes for public-health programmes. Serum’s reach across international immunisation programmes gives it importance well beyond the Indian market.

Scale can help lower unit costs and improve availability, but vaccine makers also face demanding regulatory oversight, production complexity and the challenge of matching capacity with changing public-health needs. Serum’s history is a reminder that a privately owned company can become a major actor in global health infrastructure.

Intas: formulations, specialty medicines and global markets

An Intas facility. Photo supplied for this Biz Masala feature.

Intas Pharmaceuticals, headquartered in Ahmedabad, has grown into a vertically integrated formulation development, manufacturing and marketing business. Its official profile says it operates in more than 85 countries, with international markets—particularly Europe and North America—playing an important role in its business.

Intas spans generics and specialty areas, including oncology and biosimilars. Its global network operates through Accord Healthcare and other subsidiaries. Competing in regulated markets demands substantial investment in research, regulatory submissions, manufacturing compliance and commercial infrastructure. It is a different route to international scale from Hetero’s prominent API and generic-manufacturing base, though the businesses share the need for quality and execution.

Intas also illustrates an important nuance in the word “unlisted”: a company can be constituted as a public limited company under Indian law while remaining unlisted on stock exchanges. Corporate form and stock-market status are not the same thing.

Bharat Biotech: research-led vaccine innovation

Bharat Biotech’s brand identity. Image supplied for this Biz Masala feature.

Bharat Biotech began operations in 1996, founded by Dr. Krishna M. Ella and Suchitra Ella, with an ambition to build a research-led vaccine and biotherapeutics company. Its portfolio and history include vaccines such as ROTAVAC and Typbar TCV, alongside its high-profile role in developing COVAXIN during the COVID-19 pandemic.

The company represents a different part of the unlisted landscape: a science-led enterprise where intellectual property, clinical development, manufacturing and public-health partnerships all matter. Its experience also highlights the risks and demands of vaccine innovation—clinical evidence, regulatory review, public trust and the need to manufacture consistently at scale.

For India, vaccine innovators are strategically important because they can strengthen domestic capabilities and contribute to international supply. But scientific achievement must be accompanied by transparent evidence, robust safety monitoring and dependable production.

Four companies, four routes to scale

Company	Base	Core strength	What makes it notable
Hetero	Hyderabad	APIs, generics, biosimilars	Integrated manufacturing and global reach
Serum Institute	Pune	Vaccines and biologicals	Large-scale vaccine supply for immunisation
Intas	Ahmedabad	Formulations, specialty drugs, biosimilars	Strong international-market footprint
Bharat Biotech	Hyderabad	Vaccines and biotherapeutics	Research-led vaccine development

Why remain unlisted?

Staying off the public markets can give owners more control over strategy and timing, and can reduce the pressure to respond to quarterly market expectations. It may also allow long-term investment decisions to be made with fewer public-market constraints. But private or unlisted status does not eliminate accountability: companies still face company-law requirements, tax rules, lender and investor scrutiny, product regulation and the commercial consequences of poor execution.

The trade-off is access to capital and transparency. Listed companies can raise equity from public investors and provide market liquidity, but must meet extensive disclosure and governance obligations. Unlisted companies may rely more on internal cash generation, borrowing, private investors or strategic transactions. The right structure depends on ownership goals, capital needs and the stage of the business.

The questions that matter more than valuation rumours

Because unlisted companies do not have a continuously quoted market price, claims about their valuations can circulate without the same public scrutiny as listed-company market capitalisations. Readers should be careful to distinguish revenue, profit, enterprise value, equity value and a promoter’s personal wealth. They are different measures, and a valuation estimate should not be presented as confirmed unless supported by a credible transaction or a clearly documented valuation.

For these companies, the more meaningful indicators are often operational: investment in research, regulatory approvals, manufacturing reliability, export-market access, product launches, quality performance and the ability to develop new therapies. Those are the factors that determine whether size becomes durable strength.

The Biz Masala perspective

India’s unlisted pharmaceutical giants are not a single category. Hetero’s strength in APIs and generics, Serum Institute’s vaccine scale, Intas’s formulation and specialty-drug footprint, and Bharat Biotech’s vaccine innovation show how different business models can build global influence without a public stock-market listing.

Their stories also point to a common test: can they keep translating science into dependable products, maintain trust in quality, invest for the next generation of medicines and expand access without losing operational discipline? In pharmaceuticals, scale creates opportunity—but quality and credibility are what sustain it.

Sources and editorial notes

·       Hetero — company overview and global presence: https://www.hetero.com/who-we-are

·       Hetero — official leadership profile: https://hetero.com/leadership

·       Serum Institute of India — company overview: https://www.seruminstitute.com/about_us.php

·       CRISIL Ratings — Serum Institute company and ownership profile (March 2025): https://www.crisilratings.com/mnt/winshare/Ratings/RatingList/RatingDocs/SerumInstituteofIndiaPrivateLimited_March%2020_%202025_RR_362970.html

·       Intas Pharmaceuticals — official overview: https://www.intaspharma.com/about-us/overview/

·       Bharat Biotech — company history and milestones: https://bharatbiotech.com/history_milestones.html

·       Bharat Biotech — founder profile: https://ftp.bharatbiotech.com/founder_profile.html

Editorial note: Company footprint and product descriptions are based on company-published information. Descriptions such as “largest” are attributed to the company or relevant cited source. This feature does not assign private valuations or imply that all unlisted companies share the same legal structure.

BIZ MASALA  •  BUSINESS | PEOPLE | IDEAS | INSIGHT